LinusBio today announced it raised over $16 million in Series A funding to deliver a novel platform that bridges genomics, the environment, and biological response.

The round was led by GreatPoint Ventures and Bow Capital. Other investors included Divergent Investments, Nicole Shanahan (President, Bia-Echo Foundation), the David Bellet Family Office, Gillian Sandler, and Sanford Robertson (Co-Founder of Francisco Partners and former board member of Salesforce), among others.

LinusBio is a patient-centric, breakthrough science precision exposome medicine company headquartered in New York, NY. The Company's program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.